|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||345.439 g·mol−1|
|3D model (JSmol)|
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" As of 2016[update] it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
- Frishman WH, Goldberg RJ, Benfield P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris". Drugs. 35 (1): 1–21. doi:10.2165/00003495-198835010-00001. PMID 2894292.
- Vaughan Williams EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions". Journal of Clinical Pharmacology. 27 (7): 450–60. doi:10.1002/j.1552-4604.1987.tb03049.x. PMID 2888789.
- McPherson EM (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563.
- "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989.
- Wong GW, Boyda HN, Wright JM (March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 3: CD007451. doi:10.1002/14651858.CD007451.pub2. PMC 6486283. PMID 26961574.